trial · primary record
SUN-627
Primary Progressive Multiple Sclerosis
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2027-07 |
| Primary endpoint | Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placebo |
| Registry ID | NCT07840326 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:42:02.442Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07840326
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.